Effects of intravenous iron on hypoxic pulmonary responses in COPD - Intravenous iron in COPD

niversity of Oxford0 个研究点目标入组 48 人开始时间: 2012年10月3日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Patients with a diagnosis of COPD, with at least mild disease (stage II – IV on GOLD criteria classification, FEV1 <80% predicted and FEV1/ FVC <70%)
•Significant smoking history (>15 pack years, where a pack year is the product of [average number of cigarettes smoked per day] and [number of years smoked for] divided by 20) or other definite cause of COPD
•Potential to have stable COPD at study initiation
•Able (in the Investigators opinion) and willing to comply with all study requirements.
•Participant is willing and able to give informed consent for participation in the study.
•Male or Female, aged 18 years or above.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 24
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 24

•Exclusion Criteria
•Pregnant or breast feeding
•Females who are pregnant, lactating, planning pregnancy during the course of the study or of childbearing potential unless using effective contraception for the duration of the study
•Patients taking iron supplements (in the last six weeks) or who have had a blood transfusion in the last 6 months
•Iron overload, defined as ferritin > 300 microg/L
•Hypersensitivity to previous iron infusion
•Evidence of bacteraemia
•Significant renal or liver disease (as judged by the investigator)

发起方